These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 31735731

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM.
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, López-Sendón J.
    Am J Cardiol; 2021 Jun 01; 148():146-150. PubMed ID: 33667442
    [Abstract] [Full Text] [Related]

  • 5. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
    Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, Yeh RW, Arnold SV, Sperry BW, Maurer MS, Shah SJ.
    Circulation; 2020 Apr 14; 141(15):1214-1224. PubMed ID: 32078382
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators.
    Circ Heart Fail; 2017 Jun 14; 10(6):. PubMed ID: 28611125
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
    Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ.
    Circ Heart Fail; 2022 Jan 14; 15(1):e008193. PubMed ID: 34923848
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
    Rozenbaum MH, Garcia A, Grima D, Tran D, Bhambri R, Stewart M, Li B, Heeg B, Postma M, Masri A.
    Eur Heart J Qual Care Clin Outcomes; 2022 Aug 17; 8(5):529-538. PubMed ID: 33895806
    [Abstract] [Full Text] [Related]

  • 13. Tafamidis: A Novel Treatment for Transthyretin Amyloid Cardiomyopathy.
    Nawarskas JJ, Shephard EA.
    Cardiol Rev; 2020 Aug 17; 28(3):156-160. PubMed ID: 32101907
    [Abstract] [Full Text] [Related]

  • 14. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
    Shintani Y, Okada A, Morita Y, Hamatani Y, Amano M, Takahama H, Amaki M, Hasegawa T, Ohta-Ogo K, Kanzaki H, Ishibashi-Ueda H, Yasuda S, Shimazaki C, Yoshinaga T, Yazaki M, Sekijima Y, Izumi C.
    ESC Heart Fail; 2019 Feb 17; 6(1):232-236. PubMed ID: 30478886
    [Abstract] [Full Text] [Related]

  • 15. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.
    Lamb YN.
    Am J Cardiovasc Drugs; 2021 Jan 17; 21(1):113-121. PubMed ID: 33469827
    [Abstract] [Full Text] [Related]

  • 16. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
    Capovilla TM, Lalario A, Rossi M, Porcari A, Aimo A, Limongelli G, Emdin M, Merlo M, Sinagra G.
    Heart Fail Clin; 2024 Jul 17; 20(3):333-341. PubMed ID: 38844304
    [Abstract] [Full Text] [Related]

  • 17. [Diagnosis and treatment of cardiac transthyretin amyloidosis. Innovative therapy with tafamidis.].
    Legrand D, Nyssen A, Jackers L, Brogneaux C, Pirotte I, Grayet D, Lacremans D, Magnée M.
    Rev Med Liege; 2022 Jan 17; 77(1):63-68. PubMed ID: 35029343
    [Abstract] [Full Text] [Related]

  • 18. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
    Cho Y, Baranczak A, Helmke S, Teruya S, Horn EM, Maurer MS, Kelly JW.
    Amyloid; 2015 Jan 17; 22(3):175-80. PubMed ID: 26193961
    [Abstract] [Full Text] [Related]

  • 19. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN, Deeks ED.
    Drugs; 2019 Jun 17; 79(8):863-874. PubMed ID: 31098895
    [Abstract] [Full Text] [Related]

  • 20. Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real-World Data.
    Müller ML, Latinova E, Brand A, Mattig I, Spethmann S, Messroghli D, Hahn K, Landmesser U, Heidecker B.
    J Am Heart Assoc; 2024 Jul 16; 13(14):e033478. PubMed ID: 38958150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.